Cargando…
Spoilt for choice: different immunosuppressive potential of anaplastic lymphoma kinase inhibitors for non small cell lung cancer
INTRODUCTION: Several anaplastic lymphoma kinase (ALK)-inhibitors (ALKi) have been approved for the treatment of ALK-translocated advanced or metastatic Non Small Cell Lung Cancer (NSCLC), amongst crizotinib and alectinib. This forces physicians to choose the most suitable compound for each individu...
Autores principales: | Heine, Annkristin, Held, Stefanie Andrea Erika, Daecke, Solveig Nora, Flores, Chrystel, Brossart, Peter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10562553/ https://www.ncbi.nlm.nih.gov/pubmed/37822928 http://dx.doi.org/10.3389/fimmu.2023.1257017 |
Ejemplares similares
-
The VEGF-Receptor Inhibitor Axitinib Impairs Dendritic Cell Phenotype and Function
por: Heine, Annkristin, et al.
Publicado: (2015) -
The PI3Kδ inhibitor idelalisib impairs the function of human dendritic cells
por: Braun, Christiane, et al.
Publicado: (2021) -
Analysis of the anti-proliferative and the pro-apoptotic efficacy of Syk inhibition in multiple myeloma
por: Koerber, Ruth-Miriam, et al.
Publicado: (2015) -
Elotuzumab spares dendritic cell integrity and functionality
por: Schlaweck, Sebastian, et al.
Publicado: (2021) -
Baseline immune signature score of Tregs × HLA-DR(+)CD4(+) T cells × PD1(+)CD8(+) T cells predicts outcome to immunotherapy in cancer patients
por: Mispelbaum, Rebekka, et al.
Publicado: (2022)